POMC and congenital adrenal hyperplasia: In two recent phase 2 clinical trials including adult patients with CAH, oral tildacerfont reduced ACTH, 17-hydroxyprogesterone and androstenedione for up to 12 weeks; normalization of ACTH and androstenedione was achieved in 40-60% of the patients according to dosage (83).